Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)
Federal funding opportunity FOR-TR-27-002 from National Institutes of Health.
View forecast on Grants.gov →Forecasted — not yet open
- Posted
- June 27, 2025
- Closes
- See announcement
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.350
- Category
- Health
Program funding history
Awards made under Assistance Listing 93.350 across FY2024–FY2026, from public federal spending records.
- FY2024 obligated
- $588.2M
- FY2025 obligated
- $599.3M
- FY2026 (to date) obligated
- $281.4M
- Awards in window
- 886
Top recipients: Vanderbilt University Medical Center, Regents of the University of Michigan, University of Pittsburgh - of the Commonwealth System of Higher Education, Icahn School of Medicine at Mount Sinai, The Johns Hopkins University
Source: USAspending.gov · refreshed July 2026
Synopsis
The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine.
The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe), is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration.
Areas of interest for ExTReMe could include, but are not limited to:
- direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies);
- designer EVs (personalized to the individual patient’s needs).
Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network
Who can apply
- County governments
- Public and State controlled institutions of higher education
- Public housing authorities/Indian housing authorities
- State governments
- Independent school districts
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Native American tribal governments (Federally recognized)
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.
Similar grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
Never miss a funding deadline again
Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.
Get funding alerts